Siftr Bio is focused on developing the next generation of antibody-drug conjugates (ADCs) with high efficacy and low side effects for difficult-to-treat cancers, utilizing human patient tumor tissue for linker development
Siftr Bio is focused on developing the next generation of antibody-drug conjugates (ADCs) with high efficacy and low side effects for difficult-to-treat cancers, utilizing human patient tumor tissue for linker development.